by Raynovich Rod | Mar 6, 2012 | BIOgraph, Biopharmaceuticals
Smaller Cap Biotechs In Major Correction All the major indices are down in the 1.75% range and now the NASDAQ at 2902 is 100 pts. away from the elusive 3000 level. Analysts have been warning about a correction for weeks but with many indices up 10-15% YTD profit...
by Raynovich Rod | Mar 5, 2012 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Pause Mode Since February 15 The biotech indices and ETF’s we track are off about 1% or more today as the market is in a profit taking mode. The Rayno Life Science Portfoio is also off about 1%. Speculative appetite is down with some MO stocks and former...
by Raynovich Rod | Feb 28, 2012 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Not A Good Time To Overweight Biotech Positions We are still in a holding pattern and recommend that caution be exercised regarding new positions. Although biotech stocks have made a nice run over the past five days driven by News from Vivus (VVUS) and Threshold...
by Raynovich Rod | Feb 21, 2012 | Biopharmaceuticals, Macro
Have you read the book “Think Fast,Think Slow” by Daniel Kahneman? Well my System 1 (fast, intuitive and emotional) brain sees a lot of red on the screen telling me to take profits. If you want System 2 (slower, more deliberative, more logical) data to...
by Raynovich Rod | Feb 17, 2012 | BIOgraph, Biopharmaceuticals
$11B bet on Pharmasset acquisition for Hepatitus -C drug hits a snag Gilead announced that a majority (6/8) of the hepatitis C genotype-1 patients experienced a viral relapse when treated with GS-7977 Plus Ribavirin. Additional data will be forthcoming by the end of...
by Raynovich Rod | Feb 15, 2012 | Biopharmaceuticals, Macro
Market Reversal and a Light Sell-Off Technicals and a market reversal particularly a $20+ drop in AAPL gives us reason to take profits or hedge after a great start to 2012. The S&P is up 7% YTD, NAZ up 12% YTD, and the IBB biotech ETF up 16% YTD near its all...
by Raynovich Rod | Feb 13, 2012 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Who Does Not Know About the Bull Market in Biotech Stocks? The bull market in life science stocks gathered momentum today as the IBB rallied 2.34% (up 16.6% YTD) approaching its all time high of $122.45. At some point in time we need to have a correction as this rally...
by Raynovich Rod | Feb 1, 2012 | BIOgraph, Biopharmaceuticals
The IBB hit another new high today at $118.85 as the biotech bull market rolls on. Our index of biopharmaceutical stocks were up 4% at one time propelled by Medivation (MDVN $67.67) up 22% on favorable clinical news on its prostate cancer drug. A WSJ story helped move...
by Raynovich Rod | Jan 27, 2012 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph, Biopharmaceuticals
Rayno Life Science Biopharmaceutical Picks Beat All Sector Averages Life Science Market Hits 10 Year High Tracked by IBB ($115.51), and Up 46% Over 5 years Highlights of Rayno Biopharma Portfolio Biggest winners over 3 years were Alexion, Biogen, Micromet, Regeneron,...
by Raynovich Rod | Jan 26, 2012 | BIOgraph, Biopharmaceuticals
M&A Trend Picks Up Steam The beat goes on as Amgen agrees to buy Micromet (MITI $10.95) for $1.16B.Micromet is focused on treatment of hematologic malignancies with its BiTE monoclonal antibody platform and has four clinical stage product candidates. The stock...
